|
Post by esstan2001 on Apr 6, 2017 6:53:23 GMT -5
No, this IS your idea. I read about it in another post I believe. The unique name is great idea! and the price point. all inspired! What did Mike say when you offered it up free of charge? Mike was pretty new to MNKD last June. I am not really sure he really understood what I was talking about. I told him the only thing which would save afrezza was technology; CGMS hooked to the cloud; teledocs and telecoaches. I told him what the Endo at the ADCOM said about afrezza crushing his practice and Endos were not his friend. I told him it was not packaged properly and pharmacy's would have an issue with refrigeration space and there was absolutely no reason it needed to be refrigerated if it was going to be used in 2 years. I told him he better think about selling direct to address this. I told him more things, probably too much because at the end I think he thought I was a nut. I turned to the lady who was with me as we were leaving and I told her I think he thinks I am crazy. She said he was listening. A year later I think he is starting to get it. Stefan Schwarz has this right. He said in May '15 he needed to take a different direction and he knows the big market is the T2s and that 90% of them are treated by PCPs. I am absolutely convinced including by my own personal experience is if you take a new T2, put them on insulin and get their FBG below 100 within 3 hours of eating most will be put into remission and some will actually see significant improvements. My eyesight was getting really bad, I have not felt better in years and I hardly even use reading glasses anymore. If they can get the FBG into the low 90's or 80's on their own with diet and exercise, great but most can't. My friends best friend is a physical therapist. By the time he was diagnosed his BG was shy of 300. His doctor wanted him to go on metformin and then he read all the bad things about it. I found out yesterday he had already read some reports of it being associated to dementia. He has been starving himself and exercising hours per day. His FBG is now around 120. I have told him its time for afrezza but he really thinks he is going to do it with no medication. I gave him my protocol and now I think he is close to giving it a try. This guy is atypical. Most can not attempt to do what he is trying to do but the bottom line is he has too much damage and his beta cells need a rest. As I have told him with afrezza there is no need to go crazy starving and going over the top with exercising. Get the pancreas back into shape and then eat and exercise in moderation. Diabetes is an engineering flow control problem. We have used realtime sensors for years for flow control. The medical world is 20+ years behind the times. afrezza needs the technology to catch up. Excellent analogy; awesome post seyhey.
|
|
|
Post by boca1girl on Apr 6, 2017 7:45:55 GMT -5
In response to the comparison of Tesla to Mannkind:
Tesla is making headlines frequently and the whole world knows who Elon Musk is. Tesla is losing money, recently sold more shares, and it's stock price is at an all time high.
Mannkind has a breakthrough treatment for diabetes, now a pandemic, and "no one" has even heard of Afrezza. Would anyone not associated with MNKD know who the CEO is? MNKD is losing money, recently had to perform a reverse split, and it's stock is at an all time low.
Tesla is fighting the entrenched sales/distribution model and making excellent progress. We need some consulting help from the successful folks at Tesla. Matt (or a new CEO) needs to be out in front of the media getting the word out on Afrezza and the other products in the pipeline.
|
|
|
Post by zuegirdor on Apr 6, 2017 13:09:47 GMT -5
No, this IS your idea. I read about it in another post I believe. The unique name is great idea! and the price point. all inspired! What did Mike say when you offered it up free of charge? Mike was pretty new to MNKD last June. I am not really sure he really understood what I was talking about. I told him the only thing which would save afrezza was technology; CGMS hooked to the cloud; teledocs and telecoaches. I told him what the Endo at the ADCOM said about afrezza crushing his practice and Endos were not his friend. I told him it was not packaged properly and pharmacy's would have an issue with refrigeration space and there was absolutely no reason it needed to be refrigerated if it was going to be used in 2 years. I told him he better think about selling direct to address this. I told him more things, probably too much because at the end I think he thought I was a nut. I turned to the lady who was with me as we were leaving and I told her I think he thinks I am crazy. She said he was listening. A year later I think he is starting to get it. Stefan Schwarz has this right. He said in May '15 he needed to take a different direction and he knows the big market is the T2s and that 90% of them are treated by PCPs. I am absolutely convinced including by my own personal experience is if you take a new T2, put them on insulin and get their FBG below 100 within 3 hours of eating most will be put into remission and some will actually see significant improvements. My eyesight was getting really bad, I have not felt better in years and I hardly even use reading glasses anymore. If they can get the FBG into the low 90's or 80's on their own with diet and exercise, great but most can't. My friends best friend is a physical therapist. By the time he was diagnosed his BG was shy of 300. His doctor wanted him to go on metformin and then he read all the bad things about it. I found out yesterday he had already read some reports of it being associated to dementia. He has been starving himself and exercising hours per day. His FBG is now around 120. I have told him its time for afrezza but he really thinks he is going to do it with no medication. I gave him my protocol and now I think he is close to giving it a try. This guy is atypical. Most can not attempt to do what he is trying to do but the bottom line is he has too much damage and his beta cells need a rest. As I have told him with afrezza there is no need to go crazy starving and going over the top with exercising. Get the pancreas back into shape and then eat and exercise in moderation. Diabetes is an engineering flow control problem. We have used realtime sensors for years for flow control. The medical world is 20+ years behind the times. afrezza needs the technology to catch up. Outstanding, informative and insightful post! Love the realtime flow control sensor analogy! "I told him more things, probably too much because at the end I think he thought I was a nut" hahahhahah That's how I always feel after walking away from spirited conversations on topics I am passionate about. I imagine watching the ball sail out of the park, slowly vanishing. Then, to my shocked horror, I realize it was probably a foul.
|
|
|
Post by tingtongtung on Apr 6, 2017 13:45:30 GMT -5
If the conspiracy thing is really true (is it, or is it just that Drs are scared of lawsuits?, but insurers sure look very suspect), what's MNKD doing to get past it? TSLA took care of "must have dealership" rule, and is moving forward to beat every car maker. TSLA doesn't have to contend with the FDA and still hasn't "taken care" of the "must have dealership rule" in several states, including Texas, Michigan, and Connecticut. It's also losing a lot more money than MannKind, although the stock has held up much better. nylefty - not sure why picked the least imp thing from my post to comment on.. Let me say this.. MNKD is done with FDA (at least to sell its product as of now), it already has approval. I understand that label change is going on.. Even with the existing label concerns, the drug should have had better script numbers. TSLA still has issues with some states. But who broke the status quo? TSLA thought it was better for them to sell directly to customers rather than share its profits with dealers, and be their hostage. They may be losing money. But, they raised enough cash, are raising cash when needed, and have enough money to obsolete the other inefficient car makers. I don't just look at the share price. I care about how they develop and how they create and sustain market for their product. TSLA is completely a new animal just like our Afrezza. It has all the issues (range, availability of charging station, duration of charging, expensive, etc...). TSLA not only designed an awesome new product, but accounted for almost all of the anticipated support issues. MNKD came up with Afrezza, an awesome drug. They should have known all the resistance given that they are in this business forever. As Al said, it's all capital, capital, capital.. Raise cash when you are comfortable, not when you are almost in the streets. MNKD screwed up every single time so far. Raised just ~30-40 mil from TASE. Just recently, did RS and not raising any cash (may be no one wanted in?, but still). Matt could just do a BK, wipe out everything and start from scratch. Unfair for us. But given their track record, they won't even do that right. I'm not saying Matt is failing. They don't seem to be seeing the bigger picture, or going very conservatively? I used to buy whenever the price fell almost every single time. I can't force myself do it anymore.. I believe in the drug. But, I hope the management looks at the bigger picture and see where they are failing, and come up with a plan, raise some cash (no BK, please!), and improve script numbers ASAP.
|
|
|
Post by seanismorris on Apr 6, 2017 14:14:19 GMT -5
That's very kind of you. The reality is Matt is failing.
In my experience company have almost zero loyalty to their shareholders. If Matt thinks a BK will solve their problems he'd do it 'in a blink of an eye'.
The problem with a BK is reduced credibility, and the need for a new source of funding. Afrezza isn't selling partly because of MannKind's low credibility to maintain supply. MannKind can't afford to have their credibility drop any lower, so a BK will be put off as long as possible.
That may be a bad thing (long term) for patents and investors (the crazy ones that are still averaging down). Instead we'll limp along until BK becomes inevitable.
I say inevitable because I don't see a marketing effort...
|
|
|
Post by LosingMyBullishness on Apr 6, 2017 14:16:56 GMT -5
TSLA doesn't have to contend with the FDA and still hasn't "taken care" of the "must have dealership rule" in several states, including Texas, Michigan, and Connecticut. It's also losing a lot more money than MannKind, although the stock has held up much better. nylefty - not sure why picked the least imp thing from my post to comment on.. Let me say this.. MNKD is done with FDA (at least to sell its product as of now), it already has approval. I understand that label change is going on.. Even with the existing label concerns, the drug should have had better script numbers. TSLA still has issues with some states. But who broke the status quo? TSLA thought it was better for them to sell directly to customers rather than share its profits with dealers, and be their hostage. They may be losing money. But, they raised enough cash, are raising cash when needed, and have enough money to obsolete the other inefficient car makers. I don't just look at the share price. I care about how they develop and how they create and sustain market for their product. TSLA is completely a new animal just like our Afrezza. It has all the issues (range, availability of charging station, duration of charging, expensive, etc...). TSLA not only designed an awesome new product, but accounted for almost all of the anticipated support issues. MNKD came up with Afrezza, an awesome drug. They should have known all the resistance given that they are in this business forever. As Al said, it's all capital, capital, capital.. Raise cash when you are comfortable, not when you are almost in the streets. MNKD screwed up every single time so far. Raised just ~30-40 mil from TASE. Just recently, did RS and not raising any cash (may be no one wanted in?, but still). Matt could just do a BK, wipe out everything and start from scratch. Unfair for us. But given their track record, they won't even do that right. I'm not saying Matt is failing. They don't seem to be seeing the bigger picture, or going very conservatively? I used to buy whenever the price fell almost every single time. I can't force myself do it anymore.. I believe in the drug. But, I hope the management looks at the bigger picture and see where they are failing, and come up with a plan, raise some cash (no BK, please!), and improve script numbers ASAP. Good points. I agree that Mike, Matt, Ray and all the other guys in the management paid for thinking should come out with something different to hack into the market. SNY standard, lukewarm approach did not work but Mike's first and second attempt of doing a focussed approach did not work out as well. I understand that they achieved a lot with the given personnel etc but in the end they have to get to the top. Right now they are hanging by their fingers which slowing go numb. There is no helicopter going to rescue them so better find a route to the top soon. If some guy at the FDA get a Hiccup so what.
|
|
|
Post by LosingMyBullishness on Apr 6, 2017 14:20:53 GMT -5
That's very kind of you. The reality is Matt is failing. In my experience company have almost zero loyalty to their shareholders. If Matt thinks a BK will solve their problems he'd do it 'in a blink of an eye'. The problem with a BK is reduced credibility, and the need for a new source of funding. Afrezza isn't selling partly because of MannKind's low credibility to maintain supply. MannKind can't afford to have their credibility drop any lower, so a BK will be put off as long as possible. That may be a bad thing (long term) for patents and investors (the crazy ones that are still averaging down). Instead we'll limp along until BK becomes inevitable. I say inevitable because I don't see a marketing effort... Speaking of marketing. They bought that digital marketing guy from Amgen. Has anyone seen any improvements in marketing yet?
|
|
|
Post by kbrion77 on Apr 6, 2017 14:29:31 GMT -5
That's very kind of you. The reality is Matt is failing. In my experience company have almost zero loyalty to their shareholders. If Matt thinks a BK will solve their problems he'd do it 'in a blink of an eye'. The problem with a BK is reduced credibility, and the need for a new source of funding. Afrezza isn't selling partly because of MannKind's low credibility to maintain supply. MannKind can't afford to have their credibility drop any lower, so a BK will be put off as long as possible. That may be a bad thing (long term) for patents and investors (the crazy ones that are still averaging down). Instead we'll limp along until BK becomes inevitable. I say inevitable because I don't see a marketing effort... Speaking of marketing. They bought that digital marketing guy from Amgen. Has anyone seen any improvements in marketing yet? About the same as the improvements of employee talent with the new Chief People Officer.
|
|
|
Post by goyocafe on Apr 6, 2017 14:50:41 GMT -5
Speaking of marketing. They bought that digital marketing guy from Amgen. Has anyone seen any improvements in marketing yet? About the same as the improvements of employee talent with the new Chief People Officer. Check out the list of employees at Mannkind on LinkedIn. The list of previous employers is interesting. Sanofi (sales reps), Dexcom (sales reps), Pfizzler (sales reps), Amgen (HR, marketing). If they were all given employee stock options as incentive, every share they've vested in or have in the queue are worthless (the caveat being if they were grants and not options, but those are far less common, but still worth a fraction of what they were if/when they were granted). If their income/compensation was tethered to stock, I wonder how they all feel today?
|
|
|
Post by goyocafe on Apr 6, 2017 15:05:57 GMT -5
That's very kind of you. The reality is Matt is failing. In my experience company have almost zero loyalty to their shareholders. If Matt thinks a BK will solve their problems he'd do it 'in a blink of an eye'. The problem with a BK is reduced credibility, and the need for a new source of funding. Afrezza isn't selling partly because of MannKind's low credibility to maintain supply. MannKind can't afford to have their credibility drop any lower, so a BK will be put off as long as possible. That may be a bad thing (long term) for patents and investors (the crazy ones that are still averaging down). Instead we'll limp along until BK becomes inevitable. I say inevitable because I don't see a marketing effort... Speaking of marketing. They bought that digital marketing guy from Amgen. Has anyone seen any improvements in marketing yet? Based on the article about him (posted elsewhere), he's a pioneer in digital health, a much broader and more technical area than digital marketing. I hope the plan is all targeted for May, 2017. TV sponsorship, TV Ads, new sales model, digital health implementation (may include IOT devices and such), possible co-promotion (big guess), and a great big kiss from the FDA with early PDUFA date on label enhancement (big wish).
|
|
|
Post by LosingMyBullishness on Apr 6, 2017 15:22:09 GMT -5
Speaking of marketing. They bought that digital marketing guy from Amgen. Has anyone seen any improvements in marketing yet? Based on the article about him (posted elsewhere), he's a pioneer in digital health, a much broader and more technical area than digital marketing. I hope the plan is all targeted for May, 2017. TV sponsorship, TV Ads, new sales model, digital health implementation (may include IOT devices and such), possible co-promotion (big guess), and a great big kiss from the FDA with early PDUFA date on label enhancement (big wish). That is going to be a BIG wish list. The daily reality check is the stock price.
|
|
|
Post by goyocafe on Apr 6, 2017 15:28:55 GMT -5
Based on the article about him (posted elsewhere), he's a pioneer in digital health, a much broader and more technical area than digital marketing. I hope the plan is all targeted for May, 2017. TV sponsorship, TV Ads, new sales model, digital health implementation (may include IOT devices and such), possible co-promotion (big guess), and a great big kiss from the FDA with early PDUFA date on label enhancement (big wish). That is going to be a BIG wish list. The daily reality check is the stock price. Yep.
|
|
|
Post by kc on Apr 6, 2017 15:44:39 GMT -5
That's very kind of you. The reality is Matt is failing. In my experience company have almost zero loyalty to their shareholders. If Matt thinks a BK will solve their problems he'd do it 'in a blink of an eye'. The problem with a BK is reduced credibility, and the need for a new source of funding. Afrezza isn't selling partly because of MannKind's low credibility to maintain supply. MannKind can't afford to have their credibility drop any lower, so a BK will be put off as long as possible.
That may be a bad thing (long term) for patents and investors (the crazy ones that are still averaging down). Instead we'll limp along until BK becomes inevitable. I say inevitable because I don't see a marketing effort... Selling the company is much better than filing bankruptcy. Once you file bankruptcy you again create the situation and perception that the product is going to go away or be discontinued.
Where is the board of directors? Sell the company or a partial interest in it to somebody who can take MannKind and Afrezza to the next level.
|
|
|
Post by kball on Apr 6, 2017 15:52:59 GMT -5
About the same as the improvements of employee talent with the new Chief People Officer. Check out the list of employees at Mannkind on LinkedIn. The list of previous employers is interesting. Sanofi (sales reps), Dexcom (sales reps), Pfizzler (sales reps), Amgen (HR, marketing). If they were all given employee stock options as incentive, every share they've vested in or have in the queue are worthless (the caveat being if they were grants and not options, but those are far less common, but still worth a fraction of what they were if/when they were granted). If their income/compensation was tethered to stock, I wonder how they all feel today? Honestly, I'm not sure whether this meant to be Pfizer, or the name mankind should have chosen instead of Afrezza. Afizzler--soon to gain traction i'm sure
|
|